Australia's most trusted
source of pharma news
Tuesday, 14 October 2025
Posted 14 October 2025 AM
Johnson & Johnson's bid to extend Stelara's patent protection to 2039 looks shaky, with IP Australia dealing a hefty blow to the effort, but the fight is not over.
This month IP Australia Delegate Dr A Lim ruled that the patent 2019346134 Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody, filed by J&J in September 2019, lacks novelty, and would therefore not be granted.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.